VistaGen Therapeutics Inc 2025年季度报告

Form10-Q (Mark One)þQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from __________ to __________. Commission File Number: 001-37761 VISTAGEN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)Nevada20-5093315 (State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) 343 Allerton AvenueSouth San Francisco, CA 94080(Address of principal executive offices including zip code) (650) 577-3600(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on whichregisteredCommon Stock, par value $0.001 pershareVTGNNasdaq Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periodthat the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days. Yes x No o Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filerequired to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during thepreceding 12 months (or for such shorter period that the registrant was required to submit such files). Yesx No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler,or a smaller reporting company.See the definitions of“large accelerated filer,”“accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use theextended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act. o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of theExchange Act). Yes o No x As of February 12, 2025, 28,862,085shares of the registrant’s common stock, $0.001 par value, wereoutstanding. Table of Contents TABLE OF CONTENTS PART I. FINANCIAL INFORMATION PART II. OTHER INFORMATION Table of Contents Table of Contents VISTAGEN THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’EQUITY(unaudited) See accompanying notes to unaudited condensed consolidated financial statements.4 Table of Contents Nine Months EndedDecember 31, Table of Contents VISTAGEN THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited) 1.Description of Business Vistagen Therapeutics, Inc., a Nevada corporation (Vistagen, theCompany,we,our, orus), is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry todevelop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a newclass of intranasal therapies called pherines. Pherines specifically and selectively bind to peripheralreceptors in human nasal chemosensory neurons, which activate olfactory bulb-to-brain neurocircuitswithout requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits anddifferentiated safety. Vistagen’s neuroscience pipeline also includes an oral prodrug with potential toimpactcertain neurological conditions involving the NMDA receptor.Vistagen is passionate aboutdeveloping transformative treatment options to improve the lives of individuals underserved by the currentstandardof care for multiple highly prevalent indications,including social anxiety disorder,majordepressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. 2.Basis of Presentation, Principles of Consolidation and Summary of Significant AccountingPolicies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared inaccordance with accounting principles generally accepted in the United States of America (U.S.GAAP)applicable to interim financial information and pursuant to the instructions of the Securities and ExchangeCommission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include allof the information and footnotes required by U.S. GAAP for complete financial statements. Further, theresults of our operations for any interim periods are not necessarily indicative of the results that may be expected for any other interim period or the full fiscal year. In the opinion of management, all normal andrecurring adjustments considered necessary for a fair presentation have been included. The condensedconsolidated balance sheet at March 31, 2024, has been derived from our audited co